What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- COPD
Peter M.A. Calverley mainly investigates COPD, Internal medicine, Exacerbation, Physical therapy and Placebo.
His study in COPD is interdisciplinary in nature, drawing from both Bronchodilator, Anesthesia, Fluticasone and Fluticasone propionate.
As part of his studies on Internal medicine, Peter M.A. Calverley often connects relevant subjects like Surgery.
His study looks at the relationship between Exacerbation and topics such as Eosinophil, which overlap with Post-hoc analysis.
His work deals with themes such as Proportional hazards model, Heart failure and BODE index, which intersect with Physical therapy.
His research in Placebo intersects with topics in Roflumilast, Adverse effect, Randomized controlled trial and Hazard ratio.
His most cited work include:
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease (1876 citations)
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. (1047 citations)
- An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea (902 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in COPD, Internal medicine, Exacerbation, Physical therapy and Intensive care medicine.
His COPD research is multidisciplinary, incorporating elements of Anesthesia, Placebo, Spirometry and Pulmonary disease.
His work carried out in the field of Internal medicine brings together such families of science as Surgery and Cardiology.
The various areas that he examines in his Exacerbation study include Corticosteroid, Budesonide, Formoterol, Post-hoc analysis and Pediatrics.
His Physical therapy research is multidisciplinary, incorporating perspectives in Obstructive lung disease, Quality of life, Disease and Cohort.
His Fluticasone propionate study deals with Salmeterol intersecting with Fluticasone.
He most often published in these fields:
- COPD (68.22%)
- Internal medicine (55.14%)
- Exacerbation (25.00%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (55.14%)
- COPD (68.22%)
- Exacerbation (25.00%)
In recent papers he was focusing on the following fields of study:
Peter M.A. Calverley spends much of his time researching Internal medicine, COPD, Exacerbation, Pulmonary disease and In patient.
His Internal medicine study frequently draws connections to other fields, such as Cardiology.
His studies deal with areas such as Intensive care medicine, Post-hoc analysis, Rate ratio, Placebo and Lung function as well as COPD.
His Placebo research is multidisciplinary, relying on both Ciprofloxacin, Sleep apnea, Anesthesia, Quality of life and Physical therapy.
His work on Severe exacerbation as part of his general Exacerbation study is frequently connected to Erdosteine, thereby bridging the divide between different branches of science.
His study on Pulmonary disease also encompasses disciplines like
- MEDLINE, which have a strong connection to Disease progression, Remote patient monitoring and Lung,
- Inhalation most often made with reference to Inhaled corticosteroids,
- Cigarette smoking which intersects with area such as Chronic bronchitis and Roflumilast.
Between 2017 and 2021, his most popular works were:
- Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials (143 citations)
- Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. (89 citations)
- At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. (71 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
His primary areas of investigation include Internal medicine, COPD, Randomized controlled trial, Exacerbation and Pulmonary disease.
His Internal medicine study frequently links to adjacent areas such as Cardiology.
Peter M.A. Calverley combines subjects such as Tiotropium bromide, Rate ratio, Spirometry, Asthma and Disease with his study of COPD.
His biological study spans a wide range of topics, including Fluticasone furoate/vilanterol, Anesthesia, Fluticasone and Prospective cohort study.
His Randomized controlled trial research includes elements of Placebo, Clinical trial and Sleep medicine.
His Pulmonary disease research integrates issues from Disease progression, Observational study, Post hoc, Cohort study and Comorbidity.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
